Press Releases

WESTBURY, NY - Oct 24, 2017 - BioIVT, a leading provider of biospecimens and related services, today announced that it is sponsoring the Powering Precision Health Summit (PPHS) 2017. This conference will bring together leaders in biomarker research and translational medicine to present the latest advances in their disciplines. It will be held from Oct. 24-25 at the Charles Hotel in Cambridge, MA.

“We believe ‘precision health’ - when we concentrate on developing treatments for individuals instead of average populations - can transform the industry’s approach from reactive ‘sick care’ to proactive ‘health care.’ By monitoring biomarkers as personal indicators of good health and early warning signs of adverse effects, we can focus on disease prevention and early detection, identifying patients when they are still asymptomatic, and the probability of curing them is highest,” said Kevin Hrusovsk, founder and chairman of PPHS and a BioIVT board member.

“BioIVT is a strong proponent of precision medicine. We are committed to supporting the researchers that are advancing this important field with clinical samples, research services, and technical expertise,” said BioIVT Chief Executive Officer Jeffrey Gatz. “BioIVT concluded two important transactions earlier this year, which strengthened our precision medicine portfolio - we acquired Asterand Bioscience and its superb staff and obtained exclusive market and distribution rights to Cellaria’s novel cancer cell lines and cancer culture media in the United States and Canada.”

BioIVT now provides a broad range of high quality, well-annotated disease-state tissues and clinical biofluids, which are essential pre-requisites for researchers in this field. The company has a clinical sample bank of more than 300,000 samples, plus it has access to more than 200 IRB-approved collection sites with experience collecting samples in more than 20 different tissue and biofluid formats. Its tissue bank includes breast (ER/PR/HER2), lung (EGFR and KRAS), colorectal (KRAS and BRAF), bladder, cervical, endometrial, prostate, pancreas, and liver tumor samples, pre-screened for specific mutations, and its staff has the ability to partner with researchers on custom screening of banked specimens.

BioIVT also offers an impressive variety of cell lines, which includes cancer-associated fibroblasts, peripheral blood mononuclear cells, and immune cell subsets, characterized cancer cell lines, and primary disease state cells.

After BioIVT’s acquisition of Asterand Bioscience, it gained access to Asterand’s well-established oncology tissue sourcing network and its PhaseZERO® research services groups. As a result, BioIVT now offers a full research workflow solution, ranging from specimen sourcing through experimental design to data collection, interpretation and reporting. BioIVT scientists work collaboratively with clients to validate biomarkers, develop assays, and efficiently select drug targets and candidate therapeutics with the highest likelihood for clinical success.

Included in the PhaseZERO areas of expertise is immunohistochemistry with custom assay development for commercially available and client-generated antibodies, bispecific antibodies, antibody-drug conjugates, and biosimilars. BioIVT also has experts in ViewRNA®/RNAscope® in situ hybridization techniques and Vectra® Polaris™ Imaging System. Its scientists use those techniques, together with thorough assay development and optimization approaches, to deliver high quality, biologically relevant data.

Further information about PPHS 2017 is available at http://www.pphsummit.com.

About Powering Precision Health
Powering Precision Health is the nation's first summit dedicated to bringing the world's top physicians, scientists, innovators, investors and patient advocates together to collaborate on the latest research on new biomarkers that are revolutionizing medicine. Founded by Kevin Hrusovsky, the acclaimed thought leader and visionary in life sciences and personalized medicine, PPHS is an executive think tank of researchers and clinicians working together to transform healthcare. Addressing key therapeutic areas including neurology, cardiology, oncology and infectious disease - each year PPHS unveils groundbreaking approaches for prevention, early detection and diagnosis and precision treatment of disease. Join the movement on social media with #PPHSUMMIT on Twitter @PPHSUMMIT, Facebook @PPHSUMMIT, and LinkedIn.

About BioIVT
BioIVT, formerly known as BioreclamationIVT, is a worldwide provider of biological products to the life sciences and pharmaceutical industries. The company specializes in control and disease state-matrices manufactured from human and animal biological specimens and has recently expanded its offering to include cell processing and phenotypic screening services. This portfolio of products and services is utilized throughout the drug discovery and development research workflows and directly supports precision medicine research by coupling clinical information with numerous disease-state fluids and tissues. BioIVT’s reputation for providing exceptional customer service coupled with the highest quality biospecimens and services have made it the first-choice supplier for more than 35 years. For more information, please visit www.bioivt.com or follow the company on Twitter @BiorecIVT.